New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2013
06:25 EDTBDX, HSP, TEVA, NVSInjectable drug shortages may ease with rising interest, WSJ reports
The shortage of injectable drugs used by hospitals could ease as more healthcare companies look to become new manufacturers, Wall Street Journal reports. Becton Dickinson (BDX) became the latest player in the $7B market with yesterday's approval for an antihistamine, the paper adds. Reference Link
News For BDX;HSP;TEVA;NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 2, 2014
07:35 EDTNVSIncyte earns $60M milestone payment from Novartis related to Jakavi
Incyte (INCY) announced that it has earned a $60M milestone payment from Novartis (NVS) related to reimbursement of Jakavi in Europe. Incyte will record this amount as contract revenue in Q3, and expects to receive payment of $60M in Q4. Under the Incyte-Novartis Collaboration and License Agreement signed in 2009, Novartis received exclusive development and commercialization rights to ruxolitinib outside of the U.S. for all hematologic and oncologic indications, and sells ruxolitinib under the name Jakavi. Ruxolitinib is marketed by Incyte in the U.S. as Jakafi. The achievement of this milestone also triggers the obligation for Incyte to pay tiered, low-single digit royalties to Novartis on all future sales of Jakafi in the U.S.
October 1, 2014
16:18 EDTNVSNovartis Bioventures reports 21.3% stake in Tokai Pharmaceuticals
Subscribe for More Information
08:28 EDTHSPHospira receives FDA warning letter related to Mulgrave facility
Hospira said in a filing that on September 29 it received a warning letter from the U.S. Food and Drug Administration related to an inspection of the company’s pharmaceutical manufacturing facility in Mulgrave, Victoria, Australia. The inspection occurred February 24 through March 1, 2014. The Mulgrave, Victoria site manufactures a portion of the company’s specialty injectable pharmaceutical products. The warning letter does not restrict production or shipment of the company’s pharmaceutical products from this facility. The company is evaluating what corrective actions may be required, and associated costs may be incurred, to address the matters raised in the warning letter. The company does not expect that the warning letter will impact its 2014 financial guidance. The company takes this matter seriously, and intends to respond fully and in a timely manner to the FDA’s warning letter. There can be no assurance that the FDA will be satisfied with the company’s response. Until the violations are corrected, the company may be subject to additional regulatory action by the FDA. Any such further action could, ultimately, be significant to our ongoing business and operations.
08:07 EDTNVSEnanta regains full rights to EDP-239 for Hep C virus from Novartis
Subscribe for More Information
September 30, 2014
16:39 EDTNVSCMS discloses drug makers' payments to doctors, WSJ says
Subscribe for More Information
07:30 EDTNVSSachs Associates to hold a conference
14th Annual Biotech in Europe Forum for Global Partnering and Investment to be held in Basel, Switzerland on September 30-October 1.
September 29, 2014
08:07 EDTNVSPhase 2 trial of binimetinib in NRAS melanoma shows promising clinical activity
Subscribe for More Information
07:26 EDTHSPInforma Business Information to hold a conference
Subscribe for More Information
07:19 EDTHSP, TEVAUBS to hold a field trip
Subscribe for More Information
05:26 EDTTEVAProtalix appoints Moshe Manor as CEO
Subscribe for More Information
September 26, 2014
07:30 EDTNVSNovartis drug Signifor LAR recommended by CHMP for EU approval
The Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, adopted a positive opinion for Signifor long acting release, or LAR, formulation to treat adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with a first-generation somatostatin analogue, or SSA. If approved in the EU, this next-generation SSA could fill a current unmet need, providing a new therapeutic option for the approximately 45% of acromegaly patients whose growth hormone, or GH, or insulin-like growth factor-1, or IGF-1, levels remain inadequately controlled despite treatment with currently available SSAs.
September 25, 2014
05:28 EDTNVSNovartis AIN457 meets primary endpoint in two Phase III studies
Subscribe for More Information
September 23, 2014
07:54 EDTHSPLeerink to hold a conference
Subscribe for More Information
September 22, 2014
16:07 EDTNVSAnacor announces commercial launch of KERYDIN topical solution in U.S.
Subscribe for More Information
11:24 EDTHSPHospira, Orion amend settlement agreement over Precedex
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use